Puma Biotechnology's Non Current Liabilities Total is decreasing over recent years with slightly volatile volatility. It is projected to decline toward approximately 4.5 M. From 2010 to 2026, Puma Biotechnology Non Current Liabilities Total regression analysis produced a arithmetic mean of 49,397,141 . with range of 157.3 M. View All Fundamentals
The Non Current Liabilities Total trend for Puma Biotechnology offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Puma Biotechnology is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Puma Biotechnology's Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of Puma Biotechnology over the last few years. It is Puma Biotechnology's Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Puma Biotechnology's overall financial position and show how it may be relating to other accounts over time.
Puma Non Current Liabilities Total Regression Statistics
Arithmetic Mean
49,397,141
Geometric Mean
10,420,682
Coefficient Of Variation
120.75
Mean Deviation
52,757,766
Median
5,505,000
Standard Deviation
59,649,116
Sample Variance
3558T
Range
157.3M
R-Value
0.37
Mean Square Error
3287T
R-Squared
0.13
Significance
0.15
Slope
4,322,647
Total Sum of Squares
56928.3T
Puma Non Current Liabilities Total History
2026
4.5 M
2025
4.7 M
2024
25.1 M
2023
77.7 M
2022
123 M
2021
119.4 M
2020
135.9 M
Stock Overview, Methodology & Data Sources
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company was founded in 2010 and is headquartered in Los Angeles, California. Puma Biotechnology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 196 people. The stock overview for Puma Biotechnology summarizes business drivers, financial profile, and market behavior. The company is positioned within Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Current metrics include P/E of 18.52, P/B of 2.3, profit margin of 13.62%. Puma Biotechnology has a market cap of 300.17 M, P/E of 18.52, ROE of 27.97%.
Methodology
Unless otherwise specified, financial data for Puma Biotechnology is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Puma (USA Stocks:PBYI) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Our reporting uses public filings and market reference sources and institutional disclosures from U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Normalization procedures may introduce minor timing offsets. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Puma Biotechnology has active sell-side coverage. Source-validated coverage currently shows 1 approved analyst, while broader market-consensus totals may differ across providers due to methodology and update timing. Representative analyst firms may include Bernstein Research, Deutsche Bank, Morgan Stanley, BMO Capital Markets, Guggenheim Securities, among others. Updates may occur throughout the day.
Reviewing Puma Biotechnology commonly begins with financial statements and performance trends. Ratios and trend metrics help frame Puma Biotechnology's operating context across reporting periods. Key reports that frame Puma Biotechnology Stock are listed below:
For information on how to trade Puma Stock refer to our How to Trade Puma Stock guide.Puma Biotechnology P/E of 18.52 alongside ROE at 27.97% frames the starting point - the resources below add portfolio-level context that single-security analysis cannot provide alone. That valuation within Healthcare invites comparison with Biotechnology peers using the tools below to judge whether the multiple is justified. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Quarterly Earnings Growth
-0.34
Earnings Share
0.61
Revenue Per Share
4.566
Quarterly Revenue Growth
0.277
Return On Assets
0.1085
Market capitalization and book value offer complementary views of Puma Biotechnology - the first driven by investor sentiment, the second by accounting standards. Puma Biotechnology's market capitalization is 300.17 M. A P/B ratio of 2.3 indicates the market values Puma Biotechnology above its accounting book value. Enterprise value stands at 231.19 M. Value and price for Puma Biotechnology are related but not identical, and they can diverge across cycles. Trading price represents the transaction level agreed by market participants.
The concept of value for Puma Biotechnology differs from its quoted price, since each reflects a different lens. For Puma Biotechnology, key inputs include a P/E ratio of 18.52, a P/B ratio of 2.3, a profit margin of 13.62%, and ROE of 27.97%. The actual Puma Biotechnology transaction price is determined by real-time order flow on the exchange.